SCHEMBL4458924

SCHEMBL4458924

Nc1nc(Cl)c2cnn(C(=O)O)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRAP1 Q12931 5/20 0.40
HSP90AA1 P07900 5/20 0.40
HSP90AB1 P08238 1/20 0.40
ADA P00813 1/20 0.40
HSP90B1 P14625 1/20 0.40
HDAC6 Q9UBN7 8/20 0.39
HDAC1 Q13547 6/20 0.39
HDAC4 P56524 5/20 0.39
ADORA2A P29274 3/20 0.38
ADORA1 P30542 3/20 0.38
SLC2A1 P11166 1/20 0.36
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
CSNK1A1 P48729 1/20 0.33
GSK3A P49840 1/20 0.33
LIMK1 P53667 1/20 0.33
IKBKE Q14164 1/20 0.33
MAPK14 Q16539 1/20 0.33
TAOK1 Q7L7X3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455752 0.78 ADA (0.45) TRAP1HSP90AA1HSP90AB1ADAHSP90B1
SCHEMBL17889388 0.74 PDE2A (0.47) TRAP1HSP90AA1HSP90AB1ADAHSP90B1
SCHEMBL13896214 0.73 PDE2A (0.37) TRAP1HSP90AA1HSP90AB1ADAHDAC1
SCHEMBL4452587 0.72 ADORA2A (0.70) HDAC1ADORA2AADORA1
SCHEMBL3395737 0.72 HSP90AA1 (0.46) TRAP1HSP90AA1HSP90AB1ADAHSP90B1
SCHEMBL3391792 0.71 HSP90AA1 (0.61) TRAP1HSP90AA1HSP90AB1ADAHSP90B1
SCHEMBL8221333 0.70 HSP90AA1 (0.52) TRAP1HSP90AA1HSP90AB1HSP90B1HDAC1
SCHEMBL31403622 0.70 ADORA2A (0.46) TRAP1HSP90AA1HSP90AB1ADAHSP90B1
SCHEMBL20118691 0.69 HSP90AA1 (0.62) TRAP1HSP90AA1HSP90AB1HSP90B1ADORA2A
SCHEMBL8418316 0.69 ADORA2A (0.42) TRAP1HSP90AA1HSP90AB1ADAHSP90B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629349-B2 Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2009-12-08 US disclosed
EP-1349552-B1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RES LTD (GB) 2008-08-20 EP disclosed
US-7087754-B2 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2006-08-08 US disclosed
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED 2006-05-25 US disclosed
US-20040116447-A1 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS CHRNA6, CHRNA5, CNR1 TRAP1 2843/4885HSP90AA1 4561/4885HSP90AB1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.